159 related articles for article (PubMed ID: 30877106)
1. Combined Menin and EGFR Inhibitors Synergize to Suppress Colorectal Cancer via EGFR-Independent and Calcium-Mediated Repression of SKP2 Transcription.
Katona BW; Glynn RA; Paulosky KE; Feng Z; Davis CI; Ma J; Berry CT; Szigety KM; Matkar S; Liu Y; Wang H; Wu Y; He X; Freedman BD; Brady DC; Hua X
Cancer Res; 2019 May; 79(9):2195-2207. PubMed ID: 30877106
[TBL] [Abstract][Full Text] [Related]
2. Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors.
Katona BW; Hojnacki T; Glynn RA; Paulosky KE; Szigety KM; Cao Y; Zhang X; Feng Z; He X; Ma J; Hua X
Mol Cancer Ther; 2020 Nov; 19(11):2319-2329. PubMed ID: 32879052
[TBL] [Abstract][Full Text] [Related]
3. Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by
Iommelli F; De Rosa V; Terlizzi C; Monti M; Panico M; Fonti R; Del Vecchio S
Clin Cancer Res; 2018 Jul; 24(13):3126-3136. PubMed ID: 29618618
[No Abstract] [Full Text] [Related]
4. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS
Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
[TBL] [Abstract][Full Text] [Related]
7. LXRα-mediated downregulation of EGFR suppress colorectal cancer cell proliferation.
Liang X; Cao Y; Xiang S; Xiang Z
J Cell Biochem; 2019 Oct; 120(10):17391-17404. PubMed ID: 31104333
[TBL] [Abstract][Full Text] [Related]
8. S-phase kinase-associated protein 2 knockdown blocks colorectal cancer growth via regulation of both p27 and p16 expression.
Xu SY; Wang F; Wei G; Wang B; Yang JY; Huang YZ; Zhang L; Zheng F; Guo LY; Wang JN; Tang JM
Cancer Gene Ther; 2013 Dec; 20(12):690-4. PubMed ID: 24336114
[TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
11. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
12. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
14. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
15. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
17. NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis.
Shen L; Qu X; Li H; Xu C; Wei M; Wang Q; Ru Y; Liu B; Xu Y; Li K; Hu J; Wang L; Ma Y; Li M; Lai X; Gao L; Wu K; Yao L; Zheng J; Zhang J
Oncogene; 2018 Mar; 37(13):1759-1774. PubMed ID: 29343851
[TBL] [Abstract][Full Text] [Related]
18. Menin Upregulates FOXO1 Protein Stability by Repressing Skp2-Mediated Degradation in β Cells.
Jiang Z; Xing B; Feng Z; Ma J; Ma X; Hua X
Pancreas; 2019 Feb; 48(2):267-274. PubMed ID: 30629029
[TBL] [Abstract][Full Text] [Related]
19. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
[TBL] [Abstract][Full Text] [Related]
20. Cdh1-mediated Skp2 degradation by dioscin reprogrammes aerobic glycolysis and inhibits colorectal cancer cells growth.
Zhou L; Yu X; Li M; Gong G; Liu W; Li T; Zuo H; Li W; Gao F; Liu H
EBioMedicine; 2020 Jan; 51():102570. PubMed ID: 31806563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
